Polidocanol
CAS 9002-92-0
Polidocanol (CAS 9002-92-0) is a pharmaceutical compound with 0 bioactivity targets and 59 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Deep vein thrombosis | 135 | 487.134 | 10051055 |
| Peripheral vein thrombus extension | 8 | 82.413 | 10082853 |
| Skin discolouration | 21 | 56.759 | 10040829 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| POLIDOCANOL | 968170 | SU | MTHSPL |
| LAURETH-9 | 968170 | SU | MTHSPL |
| polidocanol | 968170 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Polidocanol used for in pharmaceutical contexts?
Polidocanol (CAS 9002-92-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Polidocanol?
Polidocanol has 59 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Deep vein thrombosis, Peripheral vein thrombus extension, Skin discolouration, Cholangitis, Cholecystitis acute. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Polidocanol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Laureth-50 with EU status "permitted".
What clinical phase is Polidocanol in?
No phase 1-4 clinical development badge is rendered for Polidocanol because the matched compound identifier rows do not contain a max-phase value.